Clinical Trial Update: Efficacy and Safety Study of Acetylcysteine/Doxofylline 1200/400 mg Effervescent Tablet in the Treatment of Moderate-Severe COPD. [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating the efficacy and safety of acetylcysteine/doxofylline 1200/400 mg effervescent tablets for moderate-to-severe COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Acetylcysteine/Doxofylline 1200/400 mg effervescent tablet (acetylcysteine; doxofylline)

Snippet

Sponsor: Neutec Ar-Ge San ve Tic A.Ş | Conditions: COPD | Phase 4 | Status: COMPLETED